Financial Performance - Revenue for the year ended December 31, 2025, was HKD 1,513,357, a decrease of 6.1% compared to HKD 1,611,644 in 2024[3] - Gross profit decreased by 13.1% to HKD 925,576 from HKD 1,065,329 in the previous year[3] - Annual profit fell by 21.2% to HKD 416,859, down from HKD 529,167 in 2024[3] - Basic and diluted earnings per share decreased to HKD 0.47 from HKD 0.60, a decline of HKD 0.13[3] - The total comprehensive income for the year was HKD 425,083, compared to HKD 510,597 in the previous year[7] - The operating profit for 2025 was HKD 472,239, slightly lower than HKD 576,924 in 2024, representing a decrease of 17.9%[32] - Financial income for 2025 was HKD 46,835, compared to HKD 57,274 in 2024, showing a decline of 18.2%[32] - The annual profit for 2025 was HKD 416,859, down from HKD 529,167 in 2024, a decrease of 21.2%[32] - The net profit for 2025 was HKD 416.9 million, down 21.2% from HKD 529.2 million in 2024[60] - Earnings per share for 2025 were HKD 0.47, a decline of HKD 0.13 from HKD 0.60 in 2024[60] Assets and Liabilities - Cash and bank balances increased by 25.2% to HKD 2,279,224 from HKD 1,819,753 in 2024[4] - Total assets rose by 2.2% to HKD 4,660,738 compared to HKD 4,559,525 in the previous year[4] - Total liabilities decreased from HKD 313,091,000 in 2024 to HKD 291,877,000 in 2025, representing a reduction of approximately 6.8%[9] - Non-current liabilities increased from HKD 77,737,000 in 2024 to HKD 85,029,000 in 2025, an increase of about 9.4%[9] - Current liabilities decreased from HKD 235,354,000 in 2024 to HKD 206,848,000 in 2025, a decline of approximately 12.2%[9] - The company's total equity and liabilities amounted to HKD 4,660,738,000 in 2025, compared to HKD 4,559,525,000 in 2024, indicating a growth of about 2.2%[9] Dividends - Proposed final dividend per share increased to HKD 0.37 from HKD 0.35, a rise of HKD 0.02[3] - The total dividend paid for 2025 is HKD 292,985,000 (HKD 0.35 per share), an increase from HKD 276,243,000 (HKD 0.33 per share) in 2024[50] - The company plans to pay a final dividend of HKD 0.37 per share and a special dividend of HKD 0.03 per share for 2025[60] Segment Performance - The revenue sources are analyzed based on the geographical location of the group's entities, including Hong Kong, Mainland China, and overseas markets[26] - The Hong Kong segment includes retail sales of traditional Chinese medicine products and health supplements, as well as wholesale activities[29] - The Mainland China segment focuses on wholesale health supplements and exclusive distribution of the "Tong Ren Tang" brand products outside of Mainland China[29] - The overseas segment involves retail and wholesale of traditional Chinese medicine products and health supplements, along with providing traditional Chinese medical services[29] - The segment revenue from Hong Kong for 2025 was HKD 942,294, while for mainland China it was HKD 164,873, and overseas revenue was HKD 406,190[30] Research and Development - Research and development expenses increased to HKD 11,615 in 2025 from HKD 9,128 in 2024[42] - The production and R&D base in Hong Kong has obtained GMP, ISO22000, and HACCP certifications, ensuring comprehensive quality control throughout the production process[65] - The launch of the high-end herbal toothpaste series "Gum Nourishing" marks an expansion of the product matrix, with significant achievements in technological innovation[66] - The group has successfully registered a new anti-aging product and received a national invention patent, further enriching its product resource reserves[66] Financial Reporting Standards - The group has adopted the revised Hong Kong Accounting Standard No. 21 regarding "Lack of Convertibility" for the first time, which has no impact on the financial statements as all currencies used in transactions are convertible[19] - The Hong Kong Institute of Certified Public Accountants has issued amendments to various financial reporting standards, which include examples reflecting the existing requirements regarding the use of climate-related disclosures[20] - The group has not yet applied the newly issued but not yet effective financial reporting standards in its financial statements, planning to adopt them when they become effective[21] - The new Hong Kong Financial Reporting Standard No. 18 will replace the previous Standard No. 1, introducing new requirements for the presentation of income and expenses in the profit and loss statement[23] Corporate Strategy and Development - The group aims to capture the global health consumption upgrade trend and is committed to promoting traditional Chinese medicine culture internationally[67] - The group has established a technology innovation system in collaboration with universities, enhancing the modernization and internationalization of traditional Chinese medicine[68] - The group is focusing on core business development, enhancing production quality management and technological innovation to achieve high-quality growth[64] - The group is actively expanding into overseas markets, with the launch of deer products in New Zealand, adhering to traditional production techniques while incorporating standardized processes[67] Employee and Operational Metrics - The group had 780 employees as of December 31, 2025, with employee costs amounting to HKD 224.0 million, a reduction of 10.9% from HKD 251.4 million in 2024[75] - Distribution and selling expenses decreased by 31.0% to HKD 207.1 million, accounting for 13.7% of revenue, down from 18.6% last year[81] - General and administrative expenses reduced by 4.4% to HKD 183.3 million, representing 12.1% of revenue, consistent with last year's 11.9%[82] Taxation - Total income tax expense for 2025 was HKD 87,830, a decrease from HKD 100,606 in 2024[44] - Income tax expense decreased by 12.7% to HKD 87.8 million, with an effective tax rate of 17.4%, up from 16% last year[84] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the company's accounting policies and financial performance for the year ending December 31, 2025[101] - The company has adhered to the corporate governance code as stipulated in the listing rules as of December 31, 2025[104] - All directors confirmed compliance with the standards for securities trading as outlined in the listing rules as of December 31, 2025[105]
同仁堂国药(03613) - 2025 - 年度业绩